Blog

Jul 31, 2024, 08:54

Akhil Kapoor: Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals

Akhil Kapoor, Associate Professor and Medical Oncology at TMH Varanasi, shared a post on X about a recent paper titled “Docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus Oxaliplatin-Capecitabine/5 fluorouracil (CAPOX/mFOLFOX-7) in HER2 negative advanced gastric cancers” published on JNCI.

Authors: Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, Anuj Gupta, Akhil Kapoor, Sujay Srinivas, Omshree Shetty, Poonam Jadhav, et al.

“Our Multicenter study led by Vikas Ostwal and Anant Ramaswamy published in JNCI.

Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals
Increases toxicities
More is NOT always better.

Genomic Profiling revealed:

Low incidence of microsatellite instability (1%)
High incidence of BRCA1 (7.5%) and BRCA2 (8.4%) somatic alterations. Implications??”

Source: Akhil Kapoor/X

Akhil Kapoor Anant Ramaswamy Anuj Gupta Biswajit Dubashi BRCA1 BRCA2 cancer JNCI Omshree Shetty OncoDaily Oncology Poonam Jadhav Prabhat Bhargava somatic alterations Sujay Srinivas Vikas Ostwal

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage